MA30056B1 - Formulation de precurseur de medicament contre le hcv - Google Patents

Formulation de precurseur de medicament contre le hcv

Info

Publication number
MA30056B1
MA30056B1 MA31038A MA31038A MA30056B1 MA 30056 B1 MA30056 B1 MA 30056B1 MA 31038 A MA31038 A MA 31038A MA 31038 A MA31038 A MA 31038A MA 30056 B1 MA30056 B1 MA 30056B1
Authority
MA
Morocco
Prior art keywords
formulation
against hcv
drug precursor
precursor against
butyryloxy
Prior art date
Application number
MA31038A
Other languages
English (en)
Inventor
Hashim A Ahmed
Thomas Vernon Alfredson
Kondamraj Birudaraj
Michael Thomas Brandl
Wantanee Phuapradit
Navnit Hargovindas Shah
Dimitrios Stefanidis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30056B1 publication Critical patent/MA30056B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULATION DE PRECURSEUR DE MEDICAMENT CONTRE LE HCV La présente invention concerne une composition pharmaceutique comprenant une suspension solide préparée par extrusion en fusion à chaud de chlorhydrate d'isobutyrate de (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-l-yl)-2-azido-3,4-bis-iso-butyryloxy-tétrahydrofuran-2-ylméthyle (I) et d'un copolymère séquence de polyéthylène glycol (PEG)/polypropylène glycol (PPG).
MA31038A 2005-12-14 2008-06-16 Formulation de precurseur de medicament contre le hcv MA30056B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75014605P 2005-12-14 2005-12-14
US83059406P 2006-07-12 2006-07-12

Publications (1)

Publication Number Publication Date
MA30056B1 true MA30056B1 (fr) 2008-12-01

Family

ID=37806115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31038A MA30056B1 (fr) 2005-12-14 2008-06-16 Formulation de precurseur de medicament contre le hcv

Country Status (21)

Country Link
US (1) US7795237B2 (fr)
EP (1) EP1962808B1 (fr)
JP (1) JP5649783B2 (fr)
KR (1) KR20080089344A (fr)
AR (1) AR058313A1 (fr)
AT (1) ATE482690T1 (fr)
AU (1) AU2006326130B2 (fr)
BR (1) BRPI0619890A2 (fr)
CA (1) CA2631498A1 (fr)
CR (1) CR10026A (fr)
DE (1) DE602006017257D1 (fr)
DK (1) DK1962808T3 (fr)
EC (1) ECSP088528A (fr)
IL (1) IL191791A (fr)
MA (1) MA30056B1 (fr)
NO (1) NO20082563L (fr)
PL (1) PL1962808T3 (fr)
PT (1) PT1962808E (fr)
RU (1) RU2435592C2 (fr)
TW (1) TWI382840B (fr)
WO (1) WO2007068615A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072710A2 (fr) * 2004-01-28 2005-08-11 Johns Hopkins University Medicaments et particules de transport de genes se deplaçant rapidement a travers les barrieres muqueuses
CA2660086C (fr) * 2006-08-16 2014-09-16 Novartis Ag Methode de fabrication de dispersions solides de composes therapeutiquesde cristallinite elevee
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
WO2008119659A2 (fr) * 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Composition pharmaceutique et procédé correspondant
ES2513415T3 (es) * 2009-01-21 2014-10-27 F. Hoffmann-La Roche Ag Composiciones farmacéuticas que comprenden un profármaco inhibidor de la polimerasa del VHC
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
BR112012015951A2 (pt) * 2010-01-28 2018-10-16 Hoffmann La Roche 4 azido-nucleosídeos como compostos anti-hcv
KR101858797B1 (ko) 2010-05-10 2018-05-16 유로-셀티큐 에스.에이. 히드로모르폰 및 날록손을 포함하는 제약 조성물
KR20130030261A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 활성제-무함유 과립 및 그를 포함하는 정제의 제조
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
CA3054532C (fr) * 2010-11-05 2022-07-12 The Johns Hopkins University Compositions et procedes visant a une reduction de la mucoadherence
EP2455068A1 (fr) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Composition pharmaceutique pour le traitement d'infections par VHC
TW201300106A (zh) * 2010-11-09 2013-01-01 Hoffmann La Roche 治療ｈｃｖ感染之醫藥組合物
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (fr) * 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Nanoparticules pharmaceutiques permettant un transport muqueux amélioré
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (fr) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Nanoparticles pharmaceutiques montrant du transport mucosale amélioré
EP2956138B1 (fr) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Composés thérapeutiques et utilisations de ceux-ci
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
EA030310B1 (ru) 2013-11-13 2018-07-31 Эро-Селтик С.А. Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
EP3509423A4 (fr) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
WO2018048747A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiques et leurs utilisations
EP3381479A1 (fr) * 2017-03-29 2018-10-03 ARTOSS GmbH Composition de support pour matériau de substitution osseuse

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427124T1 (de) 1996-06-26 2009-04-15 Univ Texas Heiss-geschmolzene extrudierbare pharmazeutische formulierung
JP2001520984A (ja) * 1997-10-27 2001-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 水難溶性薬剤の固態溶剤及び固体分散体
JP4101661B2 (ja) * 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
DE10208344A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20050044529A1 (en) 2003-08-20 2005-02-24 Microsoft Corporation Task library of task data for a plurality of components on a computer system
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form

Also Published As

Publication number Publication date
DK1962808T3 (da) 2010-11-08
RU2435592C2 (ru) 2011-12-10
JP2009519289A (ja) 2009-05-14
JP5649783B2 (ja) 2015-01-07
US20070202175A1 (en) 2007-08-30
TWI382840B (zh) 2013-01-21
WO2007068615A2 (fr) 2007-06-21
CR10026A (es) 2008-07-29
NO20082563L (no) 2008-07-03
IL191791A0 (en) 2008-12-29
EP1962808A2 (fr) 2008-09-03
RU2008128361A (ru) 2010-01-20
WO2007068615A3 (fr) 2007-09-07
ECSP088528A (es) 2008-07-30
ATE482690T1 (de) 2010-10-15
KR20080089344A (ko) 2008-10-06
AU2006326130B2 (en) 2011-09-22
AU2006326130A1 (en) 2007-06-21
EP1962808B1 (fr) 2010-09-29
PT1962808E (pt) 2010-10-29
IL191791A (en) 2011-06-30
DE602006017257D1 (de) 2010-11-11
AR058313A1 (es) 2008-01-30
PL1962808T3 (pl) 2011-03-31
TW200803873A (en) 2008-01-16
US7795237B2 (en) 2010-09-14
CA2631498A1 (fr) 2007-06-21
BRPI0619890A2 (pt) 2011-10-25

Similar Documents

Publication Publication Date Title
MA30056B1 (fr) Formulation de precurseur de medicament contre le hcv
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
BR0003364A (pt) Composições farmacêuticas
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
CY1112963T1 (el) Σταθερες φαρμακευτικες συνθεσεις περιεχουσες 7-υποκατεστημενα-3,5-διυδροξυεπτανοϊκα οξεα ή 7-υποκατεστημενα-3,5-διυδροξυεπτενοϊκα οξεα
TW200732309A (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
MA27927A1 (fr) Preparations pharmaceutiques
EP1894567A4 (fr) Agents pharmaceutiques concomitants et leur utilisation
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
WO2005075471A3 (fr) Composes thiazole utilises en tant qu&#39;inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1
WO2006044362A3 (fr) Antagonistes du recepteur 1 de n-sulfonylpiperidine cannabinoide
BR0209489A (pt) Composições farmacêuticas
ATE555777T1 (de) Pharmazeutische zusammensetzung
WO2005118579A3 (fr) Composes chimiques
BR0107564A (pt) Composição de gliburida
DK1432402T3 (da) Sammensætning til tilförsel af lægemiddelkombinationer
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
NO20064808L (no) Orale matrixformuleringer med licarbazepin
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
WO2004058721A3 (fr) Modulateurs a petites molecules de l&#39;activite du facteur de croissance d&#39;hepatocyte (facteur de dispersion)
WO2007064620A3 (fr) Compositions comprenant une combinaison d&#39;antagonistes ccr5 et cxcr4
ATE459600T1 (de) Substituierte pyrrolidin-2-one
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist